Overview
Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen
Status:
Unknown status
Unknown status
Trial end date:
2020-01-01
2020-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Single-center, prospective, randomized, open-label clinical trial to evaluate the 1-year efficacy and safety of rATG 3mg/kg compared to 6mg/kg in low to moderate immunological risk patients receiving low exposure tacrolimus plus everolimus (EVL) in a steroid-free protocol.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hospital Geral de FortalezaTreatments:
Antilymphocyte Serum
Immunosuppressive Agents
Thymoglobulin
Criteria
Inclusion Criteria:- Primary kidney transplant recipients, adults
Exclusion Criteria:
- PRA > 50%
- DSA > 1500 MFI
- Retransplantation
- Patients who are planning to receive mycophenolate instead of everolimus
- Patients who have planning for follow-up in another center